Start-up Payment. The Start-up Payment for each Start-up successfully completed for each Unit operating under Condition 2 equals the Start-up Cost calculated using Equation D-1.
Start-up Payment. Buyer shall pay Seller a Monthly Start Payment or “MSP” equal to the product of the Start Price (“SP”) of $1,000.00 per successful start of the Unit times the number of successful starts of the Unit in the month in response to a start request from Buyer. A start is deemed successful where the Unit has either: (i) reached its Final Physical Energy Schedule or (ii) the Unit is in a steady state of operation for one (1) hour following the initiation of the start sequence (“Successful Start”). Buyer is not obligated to pay the Start Price for unsuccessful starts or for starts not requested by Buyer. Buyer is entitled to no more than two (2) Successful Starts per day.
Start-up Payment. For Proposals without an Equity Component, KBI Biopharma requires payment of an initial fee of one third of the Cash Component portion of the service fees specified in the Proposal, prior to commencement of Services, to account for facilities preparation costs and resource allocation commitments with respect to Client’s project(s). Initial fees are due upon execution of this Agreement or the applicable Proposal, whichever occurs later. The initial fee shall be applied on a one-third pro rata basis to the invoices in the order received. As an example, a charge of $3,000 would be satisfied by application of $1,000 from the existing initial fee balance and an additional payment by Client of $2,000. Upon termination of a Proposal or this Agreement, any remaining portion of the initial fee shall be applied to any outstanding amounts due from Client under the applicable Proposal. Unless otherwise provided in this Agreement or the applicable Proposal, initial fees are non-creditable, nonrefundable, non-transferable to apply to any Services other than under the applicable Proposal. [***]Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.
Start-up Payment. The Payee shall receive a one-time non- refundable start-up payment (as listed in Attachment B-1). Note: Start-Up Payment will be made upon receipt of an invoice when a site initiation visit has been completed at the Institution provided that the following documents have been received by Sponsor: (a) fully executed Clinical Study Agreement. A.
Start-up Payment. Each month of the Delivery Term, Buyer shall pay Seller in arrears, a payment only for Start-Ups that have been verified to be Successful Scheduled Start-Ups (the “Start-Up Payment”). The Start-Up Payment shall be the Start-Up Rate specified below for each type of Start-Up multiplied by the number of Successful Scheduled Start-Ups for each type of Start-Up. The “Start-Up Rate” is as follows: $___ per Hot Scheduled Start-Up; $___ per Warm Scheduled Start-Up; and $___ per Cold Scheduled Start-Up. The Start-Up Rates shown above shall apply commencing in the first Contract Year and be indexed annually thereafter at the beginning of each successive Contract Year by ________ percent (___%). An example of the calculation of a Start-Up Payment is provided in Appendix XX.
Start-up Payment. KBI Biopharma requires payment of an initial fee of one third of the service fees specified in the Proposal, prior to commencement of Services, and before KBI Biopharma will begin facilities preparation and resource allocation commitments with respect to Client’s project(s). Initial fees are due upon execution of this Agreement or the applicable Proposal, whichever occurs later. The initial fee shall be applied to the final project invoice. Upon termination of a Proposal or this Agreement, any remaining portion of the initial fee shall be applied to any outstanding amounts due from Client under the applicable Proposal. Unless otherwise provided in this Agreement or the applicable Proposal, initial fees are non-creditable, nonrefundable, non-transferable to any Services other than under the applicable Proposal.
Start-up Payment. G1 shall pay BI an initial, non-refundable, start-up payment of [***] (the “Start-Up Payment”), which payment will cover the [***] of BI’s activities under the Pre-Launch Plan. The Start-Up Payment will be paid in two (2) equal installments on the following dates:
6.1.1 [***] to be paid within [***] of [***], and
6.1.2 Subject to Section 11.2.8, [***] to be paid within [***].
Start-up Payment. In respect of each Cold Start and Hot Start of each Unit following a Shutdown of such Unit required by a Scheduling and Dispatch Notice in excess of an aggregate of [104] [52] for each Contract year, ESI shall pay the applicable Start-up Payment set forth in Schedule [5.3] hereto. All costs in respect of any Cold Start or Hot Start not following a Shutdown shall be for the account of Seller. ESI shall make the payments pursuant to this Section [5.3] monthly in arrears.
Start-up Payment. Pursuant to a PSO and subject to section 8.4 of this Agreement, Sponsor may provide a start-up payment to CE3, which is required to initiate the Study (“Start-up Payment”) provided that such provision for Start-up Payment is specified in the applicable PSO.
Start-up Payment. KBI Biopharma requires payment of an initial fee prior to commencement of Services under each Proposal. The amount of the initial fee and the schedule for payment (if there are multiple tasks under the Proposal) shall be set forth in the Proposal. The initial fee shall be applied to the final project invoice. Upon termination of a Proposal or this Agreement, any remaining portion of the initial fee shall be applied to any outstanding amounts due from Client under the applicable Proposal. Unless otherwise provided in this Agreement or the applicable Proposal, initial fees are non-creditable, nonrefundable, non-transferable to apply to any Services other than under the applicable Proposal.
